发布求助
文献互助 智能选刊 最新文献

Hepatology最新文献

筛选
英文 中文
Reply: Liver transplantation for primary and secondary liver tumours-Patient-level meta-analyses compared to UNOS conventional indications. 回复：肝移植治疗原发性和继发性肝肿瘤-与UNOS常规适应症相比的患者水平荟萃分析。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-06-01 Epub Date: 2025-02-18 DOI: 10.1097/HEP.0000000000001272
Ruben Ciria, Daniel Aliseda, Giammauro Berardi, Fernando Rotellar, Gonzalo Sapisochin
{"title":"Reply: Liver transplantation for primary and secondary liver tumours-Patient-level meta-analyses compared to UNOS conventional indications.","authors":"Ruben Ciria, Daniel Aliseda, Giammauro Berardi, Fernando Rotellar, Gonzalo Sapisochin","doi":"10.1097/HEP.0000000000001272","DOIUrl":"10.1097/HEP.0000000000001272","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"E173-E174"},"PeriodicalIF":12.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143439709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mendelian randomization in hepatology: A review of principles, opportunities, and challenges. 肝病随机化：原理、机遇和挑战综述。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-06-01 Epub Date: 2023-10-24 DOI: 10.1097/HEP.0000000000000649
Yilin Song, Ting Ye, Lewis R Roberts, Nicholas B Larson, Stacey J Winham
{"title":"Mendelian randomization in hepatology: A review of principles, opportunities, and challenges.","authors":"Yilin Song, Ting Ye, Lewis R Roberts, Nicholas B Larson, Stacey J Winham","doi":"10.1097/HEP.0000000000000649","DOIUrl":"10.1097/HEP.0000000000000649","url":null,"abstract":"<p><p>Mendelian randomization has become a popular tool to assess causal relationships using existing observational data. While randomized controlled trials are considered the gold standard for establishing causality between exposures and outcomes, it is not always feasible to conduct a trial. Mendelian randomization is a causal inference method that uses observational data to infer causal relationships by using genetic variation as a surrogate for the exposure of interest. Publications using the approach have increased dramatically in recent years, including in the field of hepatology. In this concise review, we describe the concepts, assumptions, and interpretation of Mendelian randomization as related to studies in hepatology. We focus on the strengths and weaknesses of the approach for a non-statistical audience, using an illustrative example to assess the causal relationship between body mass index and NAFLD.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"1836-1846"},"PeriodicalIF":12.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49687376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury. 从过去到现在再到未来：特利加压素与肝肾综合征-急性肾损伤。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-06-01 Epub Date: 2024-02-14 DOI: 10.1097/HEP.0000000000000790
Andrew S Allegretti, Kavish R Patidar, Ann T Ma, Giuseppe Cullaro
{"title":"From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.","authors":"Andrew S Allegretti, Kavish R Patidar, Ann T Ma, Giuseppe Cullaro","doi":"10.1097/HEP.0000000000000790","DOIUrl":"10.1097/HEP.0000000000000790","url":null,"abstract":"<p><p>Hepatorenal syndrome (HRS) is a rare and highly morbid form of kidney injury unique to patients with decompensated cirrhosis. HRS is a physiologic consequence of portal hypertension, leading to a functional kidney injury that can be reversed by restoring effective circulating volume and renal perfusion. While liver transplantation is the only definitive \"cure\" for HRS, medical management with vasoconstrictors and i.v. albumin is a cornerstone of supportive care. Terlipressin, a V1a receptor agonist that acts on the splanchnic circulation, has been used for many years outside the United States for the treatment of HRS. However, its recent Food and Drug Administration approval has generated new interest in this population, as a new base of prescribers now work to incorporate the drug into clinical practice. In this article, we review HRS pathophysiology and diagnostic criteria, the clinical use of terlipressin and alternative therapies, and identify areas of future research in the space of HRS and kidney injury in cirrhosis.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"1878-1897"},"PeriodicalIF":12.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11322426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139728613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geographical and molecular disparity of HBV integration: Implications for hepatocarcinogenesis and clinical outcomes in HCC. HBV 整合的地域和分子差异：对 HCC 的肝癌发生和临床结果的影响。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-06-01 Epub Date: 2024-09-30 DOI: 10.1097/HEP.0000000000001111
Takahiro Kodama
{"title":"Geographical and molecular disparity of HBV integration: Implications for hepatocarcinogenesis and clinical outcomes in HCC.","authors":"Takahiro Kodama","doi":"10.1097/HEP.0000000000001111","DOIUrl":"10.1097/HEP.0000000000001111","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"1641-1642"},"PeriodicalIF":12.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver transplantation for primary and secondary liver tumors: Patient-level meta-analyses compared to UNOS conventional indications. 原发性和继发性肝脏肿瘤的肝脏移植。患者层面的荟萃分析与单一常规适应症的比较。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-06-01 Epub Date: 2024-10-28 DOI: 10.1097/HEP.0000000000001129
Ruben Ciria, Tommy Ivanics, Daniel Aliseda, Marco Claasen, Felipe Alconchel, Felipe Gaviria, Javier Briceño, Giammauro Berardi, Fernando Rotellar, Gonzalo Sapisochin
{"title":"Liver transplantation for primary and secondary liver tumors: Patient-level meta-analyses compared to UNOS conventional indications.","authors":"Ruben Ciria, Tommy Ivanics, Daniel Aliseda, Marco Claasen, Felipe Alconchel, Felipe Gaviria, Javier Briceño, Giammauro Berardi, Fernando Rotellar, Gonzalo Sapisochin","doi":"10.1097/HEP.0000000000001129","DOIUrl":"10.1097/HEP.0000000000001129","url":null,"abstract":"<p><strong>Background and aims: </strong>Liver transplant (LT) for transplant oncology (TO) indications is being slowly adopted worldwide and has been recommended to be incorporated cautiously due to concerns about mid-long-term survival and its impact on the waiting list.</p><p><strong>Approach and results: </strong>We conducted 4 systematic reviews of all series on TO indications (intrahepatic cholangiocarcinoma and perihilar cholangiocarcinoma [phCC]) and liver metastases from neuroendocrine tumors (NETs) and colorectal cancer (CRLM) and compared them using patient-level meta-analyses to data obtained from the United Network for Organ Sharing (UNOS) database considering conventional daily-practice indications. Secondary analyses were done for specific selection criteria (Mayo-like protocols for phCC, SECA-2 for CRLM, and Milan criteria for NET). A total of 112,014 LT were analyzed from 2005 to 2020 from the UNOS databases and compared with 345, 721, 494, and 103 patients obtained from meta-analyses on intrahepatic cholangiocarcinoma and phCC, and liver metastases from NET and CRLM, respectively. Five-year overall survival was 53.3%, 56.4%, 68.6%, and 53.8%, respectively. In Mantel-Cox one-to-one comparisons, survival of TO indications was superior to combined LT, second, and third LT and not statistically significantly different from LT in recipients >70 years and high BMI.</p><p><strong>Conclusions: </strong>Liver transplantation for TO indications has adequate 5-year survival rates, mostly when performed under the selection criteria available in the literature (Mayo-like protocols for phCC, SECA-2 for CRLM, and Milan for NET). Despite concerns about its impact on the waiting list, some other LT indications are being performed with lower survival rates. These oncological patients should be given the opportunity to have a definitive curative therapy within validated criteria.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"1700-1713"},"PeriodicalIF":12.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142491652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor: Liver transplantation for primary and secondary liver tumours-Patient-level meta-analyses compared to UNOS conventional indications. 致编辑的信：肝移植治疗原发性和继发性肝脏肿瘤-与UNOS常规适应症相比的患者水平荟萃分析。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-06-01 Epub Date: 2025-02-18 DOI: 10.1097/HEP.0000000000001270
Chaoshen Wu, Yibing Zhou, Yuxiao Mu, Weimin Hong, Xuli Meng, Da Qian
{"title":"Letter to the Editor: Liver transplantation for primary and secondary liver tumours-Patient-level meta-analyses compared to UNOS conventional indications.","authors":"Chaoshen Wu, Yibing Zhou, Yuxiao Mu, Weimin Hong, Xuli Meng, Da Qian","doi":"10.1097/HEP.0000000000001270","DOIUrl":"10.1097/HEP.0000000000001270","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"E171-E172"},"PeriodicalIF":12.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143439705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver transplantation for nonstandard oncological indications: Are we there yet? 针对非标准肿瘤适应症的肝移植：我们成功了吗？
IF 12.9 1区 医学
Hepatology Pub Date : 2025-06-01 Epub Date: 2024-11-04 DOI: 10.1097/HEP.0000000000001131
Beat Moeckli, Joana Rodrigues Ribeiro, Christian Toso
{"title":"Liver transplantation for nonstandard oncological indications: Are we there yet?","authors":"Beat Moeckli, Joana Rodrigues Ribeiro, Christian Toso","doi":"10.1097/HEP.0000000000001131","DOIUrl":"10.1097/HEP.0000000000001131","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"1632-1634"},"PeriodicalIF":12.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142581416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor: Optimizing MASLD treatment-A "lead-in phase" before resmetirom. 致编辑的信：优化MASLD治疗-恢复前的“导入阶段”。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-06-01 Epub Date: 2025-02-20 DOI: 10.1097/HEP.0000000000001263
Paula Iruzubieta, Marta Alonso-Peña, Carolina Jimenez-Gonzalez, Javier Crespo
{"title":"Letter to the Editor: Optimizing MASLD treatment-A \"lead-in phase\" before resmetirom.","authors":"Paula Iruzubieta, Marta Alonso-Peña, Carolina Jimenez-Gonzalez, Javier Crespo","doi":"10.1097/HEP.0000000000001263","DOIUrl":"10.1097/HEP.0000000000001263","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"E156-E157"},"PeriodicalIF":12.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
RNA nanomedicine in liver diseases. RNA纳米医学在肝脏疾病中的应用。
IF 12.9 1区 医学
Hepatology Pub Date : 2025-06-01 Epub Date: 2024-08-26 DOI: 10.1097/HEP.0000000000000606
Anita Bakrania, Yulin Mo, Gang Zheng, Mamatha Bhat
{"title":"RNA nanomedicine in liver diseases.","authors":"Anita Bakrania, Yulin Mo, Gang Zheng, Mamatha Bhat","doi":"10.1097/HEP.0000000000000606","DOIUrl":"10.1097/HEP.0000000000000606","url":null,"abstract":"<p><p>The remarkable impact of RNA nanomedicine during the COVID-19 pandemic has demonstrated the expansive therapeutic potential of this field in diverse disease contexts. In recent years, RNA nanomedicine targeting the liver has been paradigm-shifting in the management of metabolic diseases such as hyperoxaluria and amyloidosis. RNA nanomedicine has significant potential in the management of liver diseases, where optimal management would benefit from targeted delivery, doses titrated to liver metabolism, and personalized therapy based on the specific site of interest. In this review, we discuss in-depth the different types of RNA and nanocarriers used for liver targeting along with their specific applications in metabolic dysfunction-associated steatotic liver disease, liver fibrosis, and liver cancers. We further highlight the strategies for cell-specific delivery and future perspectives in this field of research with the emergence of small activating RNA, circular RNA, and RNA base editing approaches.</p>","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"1847-1877"},"PeriodicalIF":12.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41100421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor: Dynamics in liver stiffness to assess response in MASLD patients treated with resmetirom-One piece of the puzzle? 致编辑的信：动态肝硬度评估对resmetifrom治疗的MASLD患者的反应-拼图的一部分？
IF 12.9 1区 医学
Hepatology Pub Date : 2025-06-01 Epub Date: 2025-02-14 DOI: 10.1097/HEP.0000000000001265
Georg Semmler, Maja Thiele, Thomas Reiberger, Mattias Mandorfer
{"title":"Letter to the Editor: Dynamics in liver stiffness to assess response in MASLD patients treated with resmetirom-One piece of the puzzle?","authors":"Georg Semmler, Maja Thiele, Thomas Reiberger, Mattias Mandorfer","doi":"10.1097/HEP.0000000000001265","DOIUrl":"10.1097/HEP.0000000000001265","url":null,"abstract":"","PeriodicalId":177,"journal":{"name":"Hepatology","volume":" ","pages":"E160-E161"},"PeriodicalIF":12.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143412588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信